EGFR and non-small cell lung carcinoma: Furthermore, a Phase III trial of onartuzumab in combination with the small molecule HER1 inhibitor erlotinib in advanced NSCLC patients failed to show improved efficacy versus erlotinib alone (Charakidis and Boyer, 2014).